ClinicalTrials.govpublic full text
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
prostatic cancer, castration-resistant, prostate cancer, metastatic castration resistant prostate cancer (mcrpc), castration-resistant, prostate-specific membrane antigen (psma), psma-positive, radioligand therapy (rlt), lutetium (177lu) vipivotide tetraxetan, phase 2, open-label, androgen receptor pathway inhibitor (arpi), interventional
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 906579
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.